相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
Thomas Cluzeau et al.
CANCERS (2022)
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
Evan M. Cherry et al.
BLOOD ADVANCES (2021)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis
Nicholas J. Short et al.
JAMA ONCOLOGY (2020)
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML
Renato Bassan et al.
BLOOD ADVANCES (2019)
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero et al.
CELL DEATH AND DIFFERENTIATION (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
BLOOD (2016)
Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines
Dae Sik Kim et al.
ANNALS OF HEMATOLOGY (2015)
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Alan K. Burnett et al.
BLOOD (2015)
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
Je-Hwan Lee et al.
BLOOD (2011)
The Tumor Lysis Syndrome
Scott C. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
分享论文
